In vitro and in vivo antibacterial activities of DW-224a, a new fluoronaphthyridone

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 6, 2006, Pages 2261-2264

  Park, Hee Soo ^a   Kim, Hyun Joo ^a   Seol, Min Jung ^a   Choi, Dong Rack ^b   Choi, Eung Chil ^c   Kwak, Jin Hwan ^a  

^a Handong University   (South Korea)

^b DongWha Pharm Ind Co   (South Korea)

^c Seoul National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1 CYCLOPROPYL 6 FLUORO 7 [8 (METHOXYIMINO) 2,6 DIAZASPIRO[3.4]OCT 6 YL] 4 OXO 1,4 DIHYDRO[1,8]NAPHTHYRIDINE 3 CARBOXYLIC ACID; AGAR; CIPROFLOXACIN; DW 224A; GEMIFLOXACIN; MOXIFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ACINETOBACTER CALCOACETICUS; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL INFECTION; CITROBACTER FREUNDII; COAGULASE NEGATIVE STAPHYLOCOCCUS; COLONY FORMING UNIT; DILUTION; DRUG EFFICACY; ENTEROBACTER AEROGENES; ENTEROBACTER CLOACAE; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HAEMOPHILUS INFLUENZAE; IN VITRO STUDY; IN VIVO STUDY; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MORGANELLA MORGANII; MOUSE; NEISSERIA GONORRHOEAE; NONHUMAN; PRIORITY JOURNAL; PROTEUS MIRABILIS; PROTEUS VULGARIS; PSEUDOMONAS AERUGINOSA; SALMONELLA ENTERICA; SERRATIA MARCESCENS; STENOTROPHOMONAS MALTOPHILIA; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ANIMALS; ANTI-INFECTIVE AGENTS; FLUOROQUINOLONES; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; MALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; NAPHTHYRIDINES;

EID: 33744464763     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01407-05     Document Type: Article

References (11)

1. Ball, P. 2003. Adverse drug reactions: implications for the development of fluoroquinolones. J. Antimicrob. Chemother. 51(Suppl. S1):21-27.
2. Bell, J. M., J. D. Turnidge, and SENTRY Antimicrobial Surveillance Participants. 2002. High prevalence of oxacillin-resistant Staphylococcus aureus isolates from hospitalized patients in Asia-Pacific and South Africa: results from SENTRY Antimicrobial Surveillance Program, 1998-1999. Antimicrob. Agents Chemother. 46:879-881.
3. Bliss, C. I. 1985. Statistics in bioassay. Academic Press, Inc., New York, N.Y.
4. Emmerson, A. M., and A. M. Jones. 2003. The quinolones: decades of development and use. J. Antimicrob. Chemother. 51(Suppl. S1):13-20.
5. Endtz, H. P., N. van den Braak, H. A. Verbrugh, and A. van Belkum. 1999. Vancomycin resistance: status quo and quo vadis. Eur. J. Clin. Microbiol. Infect. Dis. 18:683-690.
6. Levy, S. B., and B. Marshall. 2004. Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10:s122-s129.
7. Lode, H., and M. Allewelt. 2002 Role of newer fluoroquinolones in lower respiratory tract infections. J. Antimicrob. Chemother. 49:709-712.
8. National Committee for Clinical Laboratory Standards. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6, 6th ed., vol. 23. National Committee for Clinical Laboratory Standards, Wayne, Pa.
9. Nilius, A. M., L. L. Shen, D. Hensey-Rudloff, L. S. Almer, J. M. Beyer, D. J. Balli, Y. Cai, and R. K. Flamm. 2003. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob. Agents Chemother. 47:3260-3269.
10. Oh, J.-I., K.-S. Paek, M.-J. Ahn, M.-Y. Kim, C. Y. Hong, I.-C. Kim, and J.-H. Kwak. 1996. In vitro and in vivo evaluations of LB20304, a new fluoronaphthyridone. Antimicrob. Agents Chemother. 40:1564-1568.
11. Song, J.-H., S.-I. Jung, K. S. Ko, N. Y. Kim, J. S. Son, H.-H. Chang, H. K. Ki, W. S. Oh, J. Y. Suh, K. R. Peck, N. Y. Lee, Y. Yang, Q. Lu, A. Chongthaleong, C.-H. Chiu, M. K. Lalitha, J. Perera, T. T. Yee, G. Kumarasinghe, F. Jamal, A. Kamarulzaman, N. Parasakthi, P. H. Van, C. Carlos, T. So, T. K. Ng, and A. Shibl. 2004. High prevalence of antimicrobial resistance among clinical Staphylococcus pneumoniae isolates in Asia (an ANSORP study). Antimicrob. Agents Chemother. 48:2101-2107.